Evidence map›Paper›PMID 39801681›Full record

ArticleImmuno-oncology technology2024

Adoptive cell therapy with tumor-infiltrating lymphocytes in combination with nivolumab in patients with advanced melanoma.

D König, B Kasenda, M Sandholzer, A Chirindel, A Zingg, R Ritschard, H Thut, K Glatz, E A Kappos, D Schaefer and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immuno-oncology technology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

D KönigDepartment of Biomedicine, University of Basel, Basel, Switzerland.
B KasendaDivision of Medical Oncology, University Hospital Basel, Basel, Switzerland.
M SandholzerDepartment of Biomedicine, University of Basel, Basel, Switzerland.
A ChirindelDepartment of Radiology and Nuclear Medicine, University Hospital Basel, Basel, Switzerland.
A ZinggDepartment of Biomedicine, University of Basel, Basel, Switzerland.
R RitschardDepartment of Biomedicine, University of Basel, Basel, Switzerland.
H ThutDepartment of Biomedicine, University of Basel, Basel, Switzerland.
K GlatzInstitute of Pathology and Medical Genetics, University Hospital Basel, Basel, Switzerland.
E A KapposDepartment of Plastic, Reconstructive, Aesthetic and Hand Surgery, University Hospital Basel, Basel, Switzerland.
D SchaeferDepartment of Plastic, Reconstructive, Aesthetic and Hand Surgery, University Hospital Basel, Basel, Switzerland.
C KettelhackVisceral Surgery, Clarunis University Center for Gastrointestinal and Liver Disease, University Hospital Basel and St. Claraspital Basel, Basel, Switzerland.
J PasswegInnovation Focus Cell Therapies, University Hospital Basel, Basel, Switzerland.
K BaurInnovation Focus Cell Therapies, University Hospital Basel, Basel, Switzerland.
A HolbroInnovation Focus Cell Therapies, University Hospital Basel, Basel, Switzerland.
A BuserInnovation Focus Cell Therapies, University Hospital Basel, Basel, Switzerland.
D LardinoisDepartment of Thoracic Surgery, University Hospital Basel, Basel, Switzerland.
L T JekerDepartment of Biomedicine, University of Basel, Basel, Switzerland.
N KhannaDepartment of Biomedicine, University of Basel, Basel, Switzerland.
F StennerDivision of Medical Oncology, University Hospital Basel, Basel, Switzerland.
M S MatterInstitute of Pathology and Medical Genetics, University Hospital Basel, Basel, Switzerland.
N Rodrigues MantuanoDepartment of Biomedicine, University of Basel, Basel, Switzerland.
M BinderDepartment of Biomedicine, University of Basel, Basel, Switzerland.
A ZippeliusDepartment of Biomedicine, University of Basel, Basel, Switzerland.
H LäubliDepartment of Biomedicine, University of Basel, Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) is a personalized immunotherapy. The efficacy of TIL-ACT has been demonstrated prospectively in patients with advanced melanoma but is not limited to melanoma patients. Many patients are refractory to TIL-ACT, however, or their cancer becomes resistant. Combining anti-programmed cell death protein 1 (anti-PD-1) with TIL-ACT to antagonize the immunosuppressive tumor microenvironment may synergize to enhance the antitumor potential. Material and methods: We set up the Results: Between 2020 and 2022, we enrolled 11 patients and 9 underwent a TIL transfer (median transfused cell number: 66.25 × 10 Conclusions: TIL-ACT with nivolumab is feasible and safe. Larger trials are needed to further determine the efficacy of this combination.

Indexed as

adoptive cell therapymelanomanivolumabphase I trialtumor-infiltrating lymphocytes

Identifiers

PMID39801681
PMCPMC11725098

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.